Related Experiment Videos
[Recent progress in biological therapies for cancer]
S Saji1, Y Sugiyama, K Kunieda
1Second Dept. of Surgery, Gifu University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 20, 1999
Summary
Biological Response Modifiers (BRM) therapy has evolved significantly, moving from early development through disappointment to recent advancements driven by molecular biology. Current research focuses on diverse applications and future prospects in cancer treatment.
Area of Science:
- Immunology and Cancer Therapy
- Biological Response Modifiers (BRM)
Background:
- National health insurance approval for non-specific immunomodulators like OK-432 and PSK paved the way for other BRMs.
- BRMs, including cytokines (IL-2, IL-12, IFN, TNF) and monoclonal antibodies, are widely used in cancer treatment.
Purpose of the Study:
- To review the historical development and progress of Biological Response Modifiers (BRM) therapy.
- To discuss various aspects of BRM therapy, including clinical evaluation, immunotherapy strategies, and future directions.
Main Methods:
- Review of historical data and research from Japanese societies focused on surgical cancer immunology and BRM.
- Analysis of investigations into clinical evaluation, host immunocompetency, and different immunotherapy approaches.
Main Results:
- BRM therapy progression shows a pattern: 10 years of development, 10 years of disappointment, and 5 years of significant progress due to molecular biology.
- Extensive research covers clinical evaluation, responder criteria, adjuvant immuno-chemotherapy, locoregional immunotherapy, cytokine therapy, and adoptive immunotherapy.
Conclusions:
- BRM therapy has undergone significant evolution, with molecular biology driving recent advancements.
- Future prospects for BRM therapy involve interdisciplinary approaches, addressing challenges like tumor injury and surgical stress, and exploring novel treatment strategies.